An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives

Lenouvel, Daniel; González‐Moles, Miguel Ángel; Talbaoui, Asmae; González‐Ruiz, Lucía; Ruiz‐Ávila, Isabel; Gil-Montoya, José Antonio

doi:10.1111/odi.13088

Cited by 55 publications

(50 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD-L1 positive expression was defined as at least 5% of cancer cells showing membranous staining at any of the mentioned intensities. The cut off figure of 5% has been applied in the clinical trials involving Head and cancers [23,24]. SPSS version 20 was used for statistical evaluation.…”

Section: Immunohistochemical Analysismentioning

confidence: 99%

The Expression of Programmed Death Ligand-1 within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis

Khan¹,

Syed²,

Wahab³

et al. 2020

JAMMR

View full text Add to dashboard Cite

Background: Oral squamous cell carcinoma is prevalent in South Asian countries with rising cases of its incidence and mortality. Despite advancements in treatment, survival and recurrence rates are poor. Immunotherapy is a novel therapeutic modality in immunooncology. Immune checkpoint proteins are under investigation for clinical implications amongst which Programmed Death Ligand-1 has shown valuable results in certain malignancies. Aims: To determine the immunohistochemical expression of Programmed Death Ligand-1(PD-L1) in oral squamous cell carcinoma and to find an association of Programmed Death Ligand-1 with stage and clinicopathological parameters of oral squamous cell carcinoma. Study Design: Cross-sectional study. Place and Duration of Study: Ziauddin Medical University, Karachi, 1 Year duration during 2018-2019. Methods: A total number of 140 biopsy confirmed cases of oral squamous cell carcinoma were recruited in the study. Immunohistochemical expression of Programmed Death Ligand-1 was evaluated and associated with the clinicopathological parameters of oral squamous cell carcinoma (OSCC). The data was statistically analyzed through Descriptive statistics and Chi square test by using SPSS v.20. Results: Out of 140 participants, 74% were males (n=103) and 26% were females (n=37). Programmed Death Ligand-1 positivity was observed in 62.1% of cases (n=87). The Mean age of the participants was 48.91 ± 11.7 years. The most common site of cancer involvement was buccal mucosa and majority of participants were habitual of consuming chewable products i.e. Pan, Gutka and betel nut (89; 64%). Stage III and IV tumours comprised a major portion of cases in our study. (52; 37%), (56; 40%). A statistically significant p-value was noted for the association of Programmed Death Ligand-1 with stage II and IV tumours. (P-values: 0.029, 0.001)The association of Programmed Death Ligand-1 with other variables such as age, gender, ethnicity, sites or habits was not statistically significant. Conclusion: This study concludes that the statistical significance of Programmed Death Ligand-1 expression with tumour stage is suggestive of worsening prognosis and might have detrimental effects as tumour progresses in advanced stage. Programmed Death Ligand-1 positivity in patients having oral squamous cell carcinoma could be useful in future research in the light of cancer immunotherapy which has shown success in oncology.

show abstract

Section: Immunohistochemical Analysismentioning

confidence: 99%

The Expression of Programmed Death Ligand-1 within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis

Khan¹,

Syed²,

Wahab³

et al. 2020

JAMMR

View full text Add to dashboard Cite

show abstract

“…The prognostic significance of FADD has also been validated in a recently published article reviewing the TCGA subsets for HNSCC, confirming once again its utility as a prognostic tool and its frequent upregulation (being considered by their authors as one of the “top five” altered genes in HNSCC [ 19 ]). Consequently, its therapeutic value in HNSCC has also started to be investigated, both as a single target [ 20 , 22 ] and in combination with anti-PD-L1 drugs [ 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Clinicopathological Significance of FADD Upregulation in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

González‐Moles

Ayén

González‐Ruiz

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Fas-associated death domain (FADD) upregulation, i.e., gene amplification, protein phosphorylation and/or overexpression, has shown promising prognostic implications in head and neck squamous cell carcinoma (HNSCC). This systematic review and meta-analysis aims to evaluate the clinicopathological and prognostic significance of FADD upregulation in HNSCC. We searched studies published before February 2020 through PubMed, Embase, Web of Science, Scopus and Google Scholar. We evaluated the quality of the studies included using the QUIPS tool. The impact of FADD upregulation on survival and clinicopathological variables was meta-analysed. We explored heterogeneity and their sources, conducted sensitivity analyses and investigated small-study effects. Thirteen studies (1,923 patients) met inclusion criteria. FADD immunohistochemical overexpression was statistically associated with worse overall survival (hazard ratio [HR] = 1.52, 95% confidence intervals [CI] = 1.28–1.81, p < 0.001), disease-specific survival (HR = 2.52, 95% CI = 1.61–3.96, p < 0.001), disease-free survival (HR = 1.67, 95% CI=1.29–2.15, p < 0.001), higher clinical stage (odds ratio [OR] = 1.72, 95% CI = 1.17–2.51, p = 0.005) and a large magnitude of effect with N+ status (OR = 2.36, 95% CI = 1.85–3.00, p < 0.001). FADD phosphorylation in ser-194 demonstrated no prognostic value, while no conclusive results can be drawn for FADD gene amplification. In conclusion, our findings indicate that immunohistochemical assessment of FADD overexpression could be incorporated into the prognostic evaluation of HNSCC.

show abstract

“…Interestingly, high PD-L1 on tumor-infiltrating immune cells, but not on tumor cells, has been reported as a favorable prognostic factor for SCCHN (Kim et al, 2016). Obviously, no consensus has emerged on the impact of PD-L1 on clinicopathological features and clinical outcomes for patients with SCCHN (Lenouvel et al, 2019).…”

mentioning

confidence: 99%

“…Accurate measurement and scoring of PD-L1 protein expression is difficult due to various technical and biological pitfalls (Topalian, Taube, Anders, & Pardoll, 2016), and the choice of immunohistochemical assays and scoring strategies could lead to discrepancies between different studies (Dodson et al, 2019;Lenouvel et al, 2019). Several PD-L1 diagnostic assays are commercially available, such as Ventana SP263 (durvalumab), Dako 22C3 (pembrolizumab), and Dako 28-8 (nivolumab).…”

mentioning

confidence: 99%

PD‐L1 in squamous cell carcinoma of the oral tongue shows gender‐specific association with prognosis

Wilms

Boldrup

et al. 2020

Oral Diseases

View full text Add to dashboard Cite

Objective To use alternative quantitation approaches to clarify the clinical implication of programmed cell death ligand 1 (PD‐L1) in squamous cell carcinoma of the oral tongue (SCCOT). Materials and Methods Ventana SP263 immunohistochemistry assay and a multiplicative QuickScore method were applied to quantify PD‐L1 in tumor and surrounding immune cells from 101 patients with SCCOT. Tumor‐infiltrating immune cells were estimated from bulk tissue transcriptional profiles of 25 patients. Circulating PD‐L1 levels were measured in serum from 30 patients using an electrochemiluminescence assay platform. Results We found higher tumor cell PD‐L1 levels in females than males (p = .019). For patients with low PD‐L1 in tumor cells, better survival was seen in males than females (overall survival p = .021, disease‐free survival p = .020). Tumor‐infiltrating natural killer T cells, immature dendritic cells, and M1 macrophages were positively associated with tumor cell PD‐L1 (p < .05). Conclusions Our data confirmed the significance of gender on tumor cell PD‐L1 expression and demonstrated combined effects of gender and PD‐L1 levels on clinical outcome in patients with SCCOT. The data also indicated the involvement of specific immune cell types in PD‐L1‐regulated immune evasion.

show abstract

An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives

Cited by 55 publications

References 156 publications

The Expression of Programmed Death Ligand-1 within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis

The Expression of Programmed Death Ligand-1 within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis

Prognostic and Clinicopathological Significance of FADD Upregulation in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

PD‐L1 in squamous cell carcinoma of the oral tongue shows gender‐specific association with prognosis

Contact Info

Product

Resources

About